OptiNose Inc

OptiNose Inc(OPTN)股票分析

$9.600

-0.108 (-1.13%)收盘时

Loading chart…
High
9.722
Open
9.670
VWAP
9.60
Vol
860.96K
Mkt Cap
122.08M
Low
9.480
Amount
8.27M
EV/EBITDA, TTM
241.48

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Analyst Ratings (4)

-6.25% downside
Buy
4 Buy
0 Hold
0 Sell
Current: 9.60
最低
9.00
平均
9.00
最高
9.00

HC Wainwright & Co.

2025-03-21

目标价

$9

Hold

Piper Sandler

2025-03-21

目标价

$9

Hold

Lake Street

2025-03-20

目标价

$9

Hold

Lake Street

2025-01-16

目标价

$17

Strong Buy

HC Wainwright & Co.

2025-01-03

目标价

$18

Strong Buy

估值指标

The current forward P/E ratio for OptiNose Inc (OPTN) is -3.63, compared to its 5-year average forward P/E of -4.25.

Forward P/E

Fair
5Y Average P/E
-4.25
Current P/E
-3.63
高估
-2.22
低估
-6.28

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
-15.27
Current EV/EBITDA
241.48
高估
47.55
低估
-78.08

Forward P/S

Undervalued
5Y Average P/S
1.85
Current P/S
0.92
高估
2.62
低估
1.08

事件时间线

2025-05-21 (ET)

08:28:36

Paratek Pharmaceuticals completes acquisition of Optinose

2025-03-26 (ET)

07:02:22

Optinose reports Q4 EPS (3c) vs ($1.33) last year

2025-03-21 (ET)

06:12:28

Optinose downgraded to Neutral from Buy at H.C. Wainwright

2025-03-20 (ET)

08:44:48

Optinose downgraded to Hold from Buy at Lake Street

05:52:05

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

资讯

OPTN FAQ — answered by Alphio AI

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

4 analysts cover OPTN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始